google-site-verification: googlec7193c3de77668c9.html

UK starts first vaccine trial, eight weeks into Ebola emergency

Advertisements

The Oxford Covid vaccine was estimated to have saved six million lives in the first year it was used around the world and hundreds of millions of doses have been taken.

However, the vaccine was also restricted for use in some countries because of rare blood clots which affected up to one in 100,000 people.

It is possible this vaccine carries the same risk, although this is much lower than the threat from the Bundibugyo species of Ebola which kills around a third of those infected.

Pollock said severe side effects are “very rare” and they thought “very deeply” about the implications for trials on healthy people, and that any risk would be communicated to volunteers.

“I want to stress that the Covid AstraZeneca vaccine was given to millions of people safely,” she added.

There are three other vaccines being developed for the Bundibugyo species of Ebola.

These include one from biotechnology company Moderna using their mRNA vaccine technology. The International Aids Vaccine Initiative and Public Health Vaccines, based out of the US, are using the same technique that has been proven to work for another species of Ebola, but is slower to manufacture.


BBC News

Views: 1

See also  Study suggests using neurostimulation therapies on a specific brain circuit could treat PTSD

Check Also

Emergency doctors are stressed out—and patient irritation plays a significant role

[ HBO’s emergency-department drama “The Pitt” has become a smash hit in large part because …

Thousands will have died in UK’s unprecedented May and June heatwaves

May temperatures, meanwhile, hit a new UK high of 35.1C at Kew Gardens on May …

Body’s own cell-to-cell messaging packets studied as the basis for next-generation medicines

[ Graphical Abstract. Credit: Journal of Extracellular Vesicles (2026). DOI: 10.1002/jev2.70330 The Blood and Tissue …

Leave a Reply

Available for Amazon Prime
Home cleaning services.